Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024

LeonaBio, Inc.

2023-Q3 EPS reported -$2.38

Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.
Cash, cash equivalents and investments at $172.9M as of Sept 30, down from $245.2M at Dec 31, 2022; operating cash burn $74.5M YTD.
Phase 2/3 LIFT-AD trial enrollment for fosgonimeton expected complete by Q1 2024; topline data anticipated in H2 2024.
ATH-1105 (oral ALS candidate) IND-enabling studies ongoing; first-in-human study expected in H1 2024.
New preclinical fosgonimeton data to be presented at Neuroscience 2023 (Nov 11-15) in Washington, D.C.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

LeonaBio, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.